Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allergy Therapeutics has filed a marketing authorization application (MAA) with the Swiss regulatory agency Swissmedic for Grass MATA MPL, a new formulation of Pollinex Quattro.
Subscribe to our email newsletter
Pollinex Quattro is a four injection therapeutic vaccine for the treatment of allergic conditions which offers same season relief in as little as three weeks after treatment.
Following the approval, the product is expected to be distributed by Swiss-based Teomed, acquired by Allergy Therapeutics in 2010.
Allergy Therapeutics chief executive Manuel Llobet said this is the 12th MAA submission in 2 years and marks another strategic milestone for the company as not only does it represent the first submission of the Grass MATA MPL MAA outside the EU, it also leverages the distribution capabilities of Teomed.